FCGR3A and cancer: NK cell plasticity is being exploited by new NK cell-based intervention strategies against cancer [49–51]; by recapitulating the signaling pathway responsible for CD16-dependent priming, this study evidences new aspects of NK cell adaptation in a therapeutic setting.